Criteria for Selection of Patients With High Chance of Complete or Optimal Debulking in Advanced Ovarian Cancer

The choice of treatment strategy in patients with stage IIIC‑IV ovarian cancer (OC) remains the subject of numerous discussions. The reason for this is the unsatisfactory results of randomized trials and the low frequency of primary complete debulking surgery in these studies. We conducted a retrospective analysis to evaluate the survival outcomes in patients with OC stage IIIC–IV (n=314) who underwent treatment between 1995 and 2017. The median progression free survival for primary surgery was 15.6 months, after interval debulking – 11.5 months (p=0.002, HR 0.61: 95 % CI 0.39–0.81). The primary cytoreduction significantly increased the median of overall survival by 19.6 months: from 38.0 months after interval debulking up to 57.6 months after primary cytoreduction (p=0.04, HR 0.64: 95 % CI 0.41–0.99). An increase in the number of optimal interval debulking does not lead to an improvement in the long-term results of treatment in the group of patients after neoadjuvant chemotherapy. Our analysis over the past 20 years has shown that improvement in treatment outcomes is only observed in the primary cytoreduction group due to an increase in the number of complete optimal cytoreductive surgery.

show abstract

Retrospective Analysis of Long-Term Survival Outcomes of Primary Cytoreduction and Neoadjuvant Chemotherapy in Patients With Ovarian Cancer Stage Iiic–iv

Тюляндина

Румянцев

Морхов

et al. 2018

Zlokač. opuholi

Self Cite

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Criteria for Selection of Patients With High Chance of Complete or Optimal Debulking in Advanced Ovarian Cancer

Cited by 1 publication

References 26 publications

Retrospective Analysis of Long-Term Survival Outcomes of Primary Cytoreduction and Neoadjuvant Chemotherapy in Patients With Ovarian Cancer Stage Iiic–iv

Retrospective Analysis of Long-Term Survival Outcomes of Primary Cytoreduction and Neoadjuvant Chemotherapy in Patients With Ovarian Cancer Stage Iiic–iv

Contact Info

Product

Resources

About